ARRB1 and cancer: The same group made different statements in a subsequent paper, suggesting that loss of beta-arrestin-1 in both ADC and SCC was a predictor of poor survival, and that OS of ADC patients who showed beta-arrestin-1 expression in their cancer tissues was independent of its expression level.44 Our data do not support either of these statements: we did not find any link between beta-arrestin-1 levels (neither in cancer tissue nor in plasma) and patient OS.